Amer J Perinatol 2018; 35(08): 779-784
DOI: 10.1055/s-0037-1617428
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

A Double-Blind, Randomized, Placebo-Controlled Trial of 17 Alpha-hydroxyprogesterone Caproate in the Management of Preterm Premature Rupture of Membranes

Elizabeth S. Langen
1  Department of Obstetrics and Gynecology, Stanford University, Stanford, California
2  Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan
,
Anita Sit
3  Department of Obstetrics and Gynecology, Division of General Obstetrics and Gynecology, Santa Clara Valley Medical Center, San Jose, California
,
Katie Sherwin
1  Department of Obstetrics and Gynecology, Stanford University, Stanford, California
,
Deirdre J. Lyell
1  Department of Obstetrics and Gynecology, Stanford University, Stanford, California
,
Yair J. Blumenfeld
1  Department of Obstetrics and Gynecology, Stanford University, Stanford, California
,
Yasser Y. El-Sayed
1  Department of Obstetrics and Gynecology, Stanford University, Stanford, California
› Author Affiliations
Funding The study medications were funded by divisional research funds and through a donation of study medications from the Maternal-Fetal Medicine Units (MFMU) Network. The MFMU Network was not part of the study process nor was they involved in the preparation of the article. Data for this trial were securely stored using the REDCap database system that is supported by the CTSA: UL1TR000433.
Further Information

Publication History

11 August 2017

29 November 2017

Publication Date:
03 January 2018 (eFirst)

Abstract

Objective The objective of this study was to evaluate whether weekly administration of 17 α-hydroxyprogesterone caproate (17-OHPC) increases the number of women who achieve 34 weeks of gestation after preterm premature rupture of membranes (PPROM).

Study Design We conducted a multicenter double-blind, randomized controlled trial of 17-OHPC versus placebo among women with PPROM. Women with singleton pregnancy, clinically confirmed PPROM, and without evidence of active infection or major fetal malformation between 240/7 and 320/7 weeks of pregnancy were offered enrollment. Women received weekly injections of 17-OHPC versus placebo until 340/7 weeks of gestation or delivery. The remainder of care was per hospital protocol. The primary outcome was achievement of 34 weeks of gestation. Secondary outcomes included length of latency and maternal and fetal outcomes.

Results In this study, 21 women were enrolled. Eleven women received placebo and 10 received 17-OHPC. The study was closed prematurely secondary to poor enrollment. None of the women remained pregnant until 34 weeks of gestation. The median latency periods were 8 and 14.5 days for the placebo and 17-OHPC groups, respectively (p = 0.14). There were no differences in maternal or neonatal outcomes.

Conclusion We did not identify any benefit from administration of 17-OHPC in pregnancies complicated by PPROM.

Note

Poster presentation at the 36th Annual Meeting of the Society of Maternal-Fetal Medicine, The Pregnancy Meeting, Atlanta, GA.